Integration of Obesity and Diabetes Divisions
Korean Physician Appointed as Head of CMR

Novo Nordisk Korea, which opened the domestic glucagon-like peptide-1 (GLP-1) obesity drug market with Wegovy, has carried out a large-scale organizational restructuring and executive reshuffle. This move is interpreted as a strategic shift to bolster its defense in the Korean market, as the company faces mounting challenges to its global leadership in obesity treatments from the latecomer Eli Lilly.


According to industry sources on July 7, Novo Nordisk Korea merged its obesity and diabetes divisions earlier this month. This measure, bringing together two previously separate divisions, is seen as an effort to speed up decision-making and focus resources more effectively.


Along with the organizational integration, executive appointments were also made. Earlier this month, a Korean physician with domestic pharmaceutical industry experience was appointed as Senior Director of Clinical, Medical, and Regulatory Affairs (CMR), overseeing clinical trial design and execution, medical department operations, as well as regulatory work and product approvals with the Ministry of Food and Drug Safety and other authorities.


A professor at a university hospital, who also serves as an executive member of local obesity and diabetes societies, commented, "Appointing someone familiar with the local environment instead of a foreign executive signals an intent to regain control over the Korean market."

Wegovy Strategy Overhaul? Novo Nordisk Korea Restructures Executives and Organization View original image

According to pharmaceutical data analysis platform BRP Insight, Eli Lilly's Mounjaro (active ingredient: tirzepatide) held a 78% market share in the domestic injectable obesity treatment market as of May. Wegovy (active ingredient: semaglutide) lagged behind at 15%. Despite Wegovy being the first to launch in Korea in 2024, Mounjaro, introduced in August last year, overtook it in less than a year and reshaped the market landscape.


The sales gap is also striking. In the first quarter of this year, Mounjaro recorded approximately 323.2 billion won in domestic sales, surpassing Wegovy (about 104 billion won) by more than three times. Novo Nordisk attempted to defend its position by cutting Wegovy’s wholesale price by about 40% in response to Mounjaro’s launch, but was unable to prevent a decline in market share. On top of that, Eli Lilly further expanded its lineup last month by introducing additional high-dose Mounjaro products (12.5mg and 15mg) in Korea.


Novo Nordisk’s disadvantage is not limited to Korea. In the United States, Zepbound, another tirzepatide-based obesity treatment, surpassed Wegovy by more than 100,000 weekly prescriptions, capturing close to 60% market share. The battle for market leadership that began globally is now playing out in Korea as well.


Since last year, Novo Nordisk has been overhauling its management team in response to poor performance and a declining stock price. As Wegovy’s growth slowed and its share price plummeted, the company replaced former CEO Lars Fruergaard Jorgensen with new CEO Mike Doustdar last year, transitioning to new leadership. Novo Nordisk also implemented a large-scale restructuring, cutting about 9,000 jobs—approximately 11% of its total workforce.



The domestic obesity drug market is expected to become even more competitive in the second half of the year. In addition to the duopoly between Novo Nordisk and Eli Lilly, Hanmi Pharmaceutical plans to launch the first domestically developed GLP-1 obesity drug with enhanced price competitiveness later this year. In phase 3 clinical trials, it demonstrated up to 30% weight loss efficacy, and the company is targeting annual domestic sales in the 100 billion won range.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing